Level | ES eligibility (n = 1542) | ED eligibility (n = 1542) |
---|---|---|
 | OR (95% CI) | OR (95% CI) |
Intercept | Â | Â |
Patient baseline characteristics | Â | |
Country (vs Ireland/United Kingdom) | Â | Â |
  Czech Republic | 0.91 (0.38–2.17) | 2.18 (1.01–4.67)* |
  Germany | 2.47 (1.55–3.92)*** | 2.05 (1.30–3.24)** |
  Greece | 3.30 (1.99–5.48)*** | 1.39 (0.84–2.30) |
  Portugal | 1.75 (1.04–2.95)* | 1.67 (0.99–2.83) |
  Slovakia | 0.55 (0.20–1.46) | 0.29 (0.10–0.82)* |
Patient living arrangements (vs at home with caregiver) | Â | Â |
  Alone without caregiver |  | 1.33 (1.03–1.72)* |
Dementia | 0.46 (0.28–0.76)** | 0.50 (0.30–0.83)** |
Infection/ treatment characteristics | Â | |
Hospital-acquired or healthcare-associated infection | 1.75 (1.30–2.37)*** | 1.69 (1.25–2.27)*** |
Days to first MRSA culture (vs on or before cSSTI index date) | Â | Â |
  No MRSA culture documented | 0.46 (0.30–0.69)*** | 0.58 (0.40–0.85)** |
Days from admission to cSSTI index date (vs cSSTI at admission) | Â | Â |
  ≥4 days after admission | 0.47 (0.32–0.70)* | 0.55 (0.38–0.79) |
MRSA-targeted therapy patterns (vs IV-only) | Â | Â |
  IV-to-oral antibiotic switch | 0.49 (0.33–0.72)*** | 1.40 (1.00–1.96) |
Time to initiating MRSA-active therapy (vs on or before cSSTI index date) | Â | Â |
  1–2 days post cSSTI index date |  | 1.20 (0.92–1.56)** |
  ≥3 days post cSSTI index date |  | 0.71 (0.51–0.99)** |
Any surgical procedures for cSSTI | 1.13 (0.87–1.45) | 1.04 (0.82–1.32) |
Complications | Â | |
Developed IV line infection | 0.19 (0.06–0.56)** |  |
Hospital characteristics | Â | |
Hospital had an IV-to-oral antibiotic switch protocol |  | 0.58 (0.43–0.80)*** |
Hospital had an ED protocol (IV-to-oral antibiotic switch or OPAT) |  | 1.86 (1.31–2.64)*** |